Washington Post, Americans spent $71 billion on GLP-1 drugs in 2023 (Apr. 21, 2025)

Status
Not open for further replies.
From the article: "Also in 2023, products that were approved to treat Type 2 diabetes accounted for 89 percent of all spending."

So, per Google Gemini: "This suggests that while some GLP-1 drugs are also approved for weight loss, the primary driver of the massive spending in 2023 was the use of these drugs for diabetes management."
 
From an article last April:

https://www.cnbc.com/2024/04/03/weight-loss-diabetes-drug-ad-spending-tops-1-billion.html

Companies spent more than $1 billion on ads for weight loss and diabetes medicines in 2023, up 51% from the prior year, according to new data from advertising analytics firm MediaRadar. That’s nearly 15% of drugmakers’ $7.6 billion in ad spending for prescription drugs last year.

Diabetes treatments accounted for nearly $790 million in ad spending in 2023, while weight loss drugs made up almost $264 million...

Zepbound...won approval in the U.S. in November [2023], and some analysts say it could eventually become the top-selling drug of all time.
 
Status
Not open for further replies.

Trending content

Members online

No members online now.

Forum statistics

Threads
4,464
Messages
89,269
Members
8,119
Latest member
hannahcellstrains
Back
Top